A South Korean exosome-based regenerative therapy used as an adjunctive treatment after microneedling, RF microneedling, laser resurfacing, and hair restoration protocols.
ASCE+ (Advanced Skin Care Exosomes) is a medical-grade exosome-based regenerative therapy developed by ExoCoBio Inc., a South Korean biotechnology company recognized as a pioneer in exosome research and manufacturing. Unlike hyaluronic acid fillers, polynucleotide injectables, or collagen stimulators, ASCE+ uses cell-derived exosomes to promote skin regeneration, wound healing, anti-inflammatory effects, and tissue repair. It's widely used as an adjunctive regenerative treatment following procedures such as microneedling, RF microneedling, fractional laser resurfacing, CO2 laser, chemical peels, and hair restoration protocols.
ASCE+'s defining feature is ExoSCRT™ (Exosome Secretion and Purification Technology), a proprietary platform designed to isolate highly purified exosomes, remove unwanted cellular impurities, preserve biological activity, and improve manufacturing reproducibility. The exosomes are then freeze-dried to maintain stability until reconstituted immediately before use.
Exosomes are extracellular vesicles, roughly 30 to 200 nm, naturally released by cells and carrying signaling molecules such as growth factors, messenger RNA, microRNA, proteins, and lipids. Rather than becoming part of the tissue themselves, they act as intercellular messengers that help regulate inflammation, tissue repair, collagen production, and cellular communication.
Skin Rejuvenation Lyophilized Version - post-laser recovery, microneedling, scar remodeling, collagen stimulation, skin barrier repair
Hair Regeneration Lyophilized Version - hair thinning, androgenetic alopecia, telogen effluvium, scalp regeneration
Pigmentation-related concerns and skin brightening in selected markets
Protocols vary by procedure: roughly every 3 to 4 weeks for 3 to 5 sessions when paired with microneedling, every 4 weeks with RF microneedling, applied immediately after laser treatment, or monthly for 3 to 6 sessions for hair restoration. Many clinics use ASCE+ as a combination therapy rather than a standalone treatment.
Because these risks exist with any injectable or energy-based treatment, procedures should only be performed by trained, licensed medical professionals with expertise in facial anatomy.
ASCE+ is available in more than 70 countries through professional aesthetic distributors. Regulatory classification differs between jurisdictions, with some markets treating it as a cosmetic, others as a medical device, and others under separate regenerative medicine frameworks, so clinicians verify local regulatory approval before use.
ASCE+ is considered one of the leading exosome-based regenerative platforms in aesthetic medicine. ExoCoBio has established itself as a global leader in exosome biotechnology through its ExoSCRT™ purification technology, extensive patent portfolio, and broad scientific research program. ASCE+ is particularly valued as a post-procedure regenerative therapy that helps reduce inflammation, accelerate healing, and support collagen remodeling after treatments such as microneedling, RF microneedling, and laser resurfacing. Compared with established injectable products like PROFHILO, REJURAN, or RADIESSE, ASCE+ represents a different therapeutic category focused on cell-to-cell signaling and tissue regeneration rather than volumization or direct collagen stimulation.
